Generate Biomedicines (NASDAQ: GENB) — Stock Profile

Generate Biomedicines is a United States-based biotechnology company operating at the intersection of machine learning and drug discovery, applying generative biology to the design and development of novel protein therapeutics. The company works exclusively with protein-based modalities, using computational methods to program new medicines that address conditions where conventional approaches have fallen short.

Its pipeline includes GB-0895, an investigational long-acting anti-TSLP monoclonal antibody intended for dosing every six months in patients with severe asthma, alongside GB-4362, an MMAE payload neutralizer monoclonal antibody, and GB-5267, a MUC16 CAR-T cell therapy. Underpinning these programs is the Generate Platform, a therapeutic area and protein modality agnostic system that integrates computational innovation with scalable biohardware to tackle challenges beyond the reach of traditional technologies. Formerly known as Generate Biologics, the company adopted its current name in February 2020, having been incorporated in 2018 and headquartered in Somerville, Massachusetts, United States.